Dashboard
Manage Tickers

RMDRESMED INC

NYSE resmed.com


$ 223.18 $ -8.12 (-3.51 %)    

Tuesday, 20-Aug-2024 15:59:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 480.64 $ -0.66 (-0.14 %)
DIA $ 408.54 $ -0.35 (-0.09 %)
SPY $ 558.65 $ -0.51 (-0.09 %)
TLT $ 98.68 $ 0.38 (0.39 %)
GLD $ 232.46 $ -1.26 (-0.54 %)
$ 231.3
$ 230.15
$ 223.07 x 102
-- x --
$ 222.40 - $ 231.26
$ 130.88 - $ 231.50
786,682
na
34.13B
$ 1.04
$ 33.43
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-09-2024 06-30-2024 10-K
2 04-25-2024 03-31-2024 10-Q
3 01-25-2024 12-31-2023 10-Q
4 10-26-2023 09-30-2023 10-Q
5 08-11-2023 06-30-2023 10-K
6 04-28-2023 03-31-2023 10-Q
7 01-27-2023 12-31-2022 10-Q
8 10-28-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-K
10 04-28-2022 03-31-2022 10-Q
11 01-27-2022 12-31-2021 10-Q
12 10-28-2021 09-30-2021 10-Q
13 08-17-2021 06-30-2021 10-K
14 04-30-2021 03-31-2021 10-Q
15 01-29-2021 12-31-2020 10-Q
16 10-30-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-K
18 05-01-2020 03-31-2020 10-Q
19 01-31-2020 12-31-2019 10-Q
20 10-25-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-K
22 05-03-2019 03-31-2019 10-Q
23 02-01-2019 12-31-2018 10-Q
24 10-26-2018 09-30-2018 10-Q
25 08-17-2018 06-30-2018 10-K
26 04-27-2018 03-31-2018 10-Q
27 01-24-2018 12-31-2017 10-Q
28 10-27-2017 09-30-2017 10-Q
29 08-04-2017 06-30-2017 10-K
30 04-28-2017 03-31-2017 10-Q
31 01-25-2017 12-31-2016 10-Q
32 10-28-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-K
34 04-29-2016 03-31-2016 10-Q
35 01-28-2016 12-31-2015 10-Q
36 10-27-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-K
38 04-29-2015 03-31-2015 10-Q
39 01-30-2015 12-31-2014 10-Q
40 10-31-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

1000-invested-in-resmed-10-years-ago-would-be-worth-this-much-today
$1000 Invested In ResMed 10 Years Ago Woul...
08/20/2024 19:30:13

if-you-invested-1000-in-this-stock-15-years-ago-you-would-have-9500-today
If You Invested $1000 In This Stock 15 Yea...
08/07/2024 14:00:30

doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-others-in-your-portfolio
DoorDash And Exact Sciences Are Among Top ...
08/04/2024 14:32:50

Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, ...

rbc-capital-maintains-sector-perform-on-resmed-raises-price-target-to-206
RBC Capital Maintains Sector Perform on Re...
08/02/2024 20:46:44

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $204 t...

keybanc-maintains-overweight-on-resmed-raises-price-target-to-251
Keybanc Maintains Overweight on ResMed, Ra...
08/02/2024 16:10:02

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $238 to $251.

resmed-earnings-reflect-increased-demand-for-sleep-devices-performance-indicates-positive-dynamics-opportunities
ResMed Earnings Reflect Increased Demand F...
08/02/2024 14:46:26

ResMed reported Q4 2024 revenue of $1.22 billion, driven by strong demand for sleep devices and software services. Gross margin...

resmed-shares-are-trading-lower-the-company-reported-q4-financial-results
ResMed shares are trading lower. The compa...
08/02/2024 11:37:06

needham-reiterates-buy-on-resmed-maintains-236-price-target
Needham Reiterates Buy on ResMed, Maintain...
08/02/2024 09:48:48

Needham analyst Mike Matson reiterates ResMed (NYSE:RMD) with a Buy and maintains $236 price target.

resmed-increases-quarterly-dividend-from-048-to-053
ResMed Increases Quarterly Dividend From $...
08/01/2024 20:25:32

resmed-q4-2024-adj-eps-208-beats-207-estimate-sales-1232b-beat-1217b-estimate
ResMed Q4 2024 Adj. EPS $2.08 Beats $2.07 ...
08/01/2024 20:07:50

ResMed (NYSE:RMD) reported quarterly earnings of $2.08 per share which beat the analyst consensus estimate of $2.07 by 0.48 per...

resmeds-options-frenzy-what-you-need-to-know
ResMed's Options Frenzy: What You Need to ...
07/30/2024 19:45:53

if-you-invested-1000-in-this-stock-20-years-ago-you-would-have-16000-today
If You Invested $1000 In This Stock 20 Yea...
07/26/2024 16:00:24

microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-tuesday
Microsoft To Rally Around 10%? Here Are 10...
07/23/2024 13:59:29

what-6-analyst-ratings-have-to-say-about-resmed
What 6 Analyst Ratings Have To Say About R...
07/23/2024 13:01:30

rbc-capital-maintains-sector-perform-on-resmed-raises-price-target-to-204
RBC Capital Maintains Sector Perform on Re...
07/23/2024 11:32:19

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $200 t...

looking-into-resmeds-recent-short-interest
Looking Into ResMed's Recent Short Interest
07/09/2024 17:30:15

1000-invested-in-this-stock-15-years-ago-would-be-worth-9600-today
$1000 Invested In This Stock 15 Years Ago ...
07/02/2024 18:30:27

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/26/2024 17:35:22

beyond-the-numbers-6-analysts-discuss-resmed-stock
Beyond The Numbers: 6 Analysts Discuss Res...
06/25/2024 13:02:02

oppenheimer-downgrades-resmed-to-perform
Oppenheimer Downgrades ResMed to Perform
06/25/2024 12:29:49

Oppenheimer analyst Suraj Kalia downgrades ResMed (NYSE:RMD) from Outperform to Perform.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION